ABT
Abbott LaboratoriesDNYSE / Health Care Equipment & Services
Last Price
At close
2026-07-17
Current thesis
The Q2 beat, raised adjusted EPS outlook, strong Medical Devices growth, and Exact Sciences diagnostics contribution improve confidence in Abbott's 2026 earnings trajectory. The median analyst target of $117.9048 implies roughly 19% upside from the $98.83 anchor price, though target-count data is unavailable.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.6.
What can break
Exact Sciences integration and acquisition-related charges may complicate reported earnings and cash-flow interpretation.
Momentum
25
Value
56
Sentiment
60
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $114.00 · Bull $125.00 · Bear $85.00
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-17
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $117.90
Why
Momentum25 · Δ7d -14.1
Value56 · Δ7d -0.6
Sentiment60 · Δ7d -13.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
25
26% active weight
Current posture
7d trendImproving
Δ7d
-14.1
Δ21d
-3.1
Value
56
39% active weight
Current posture
7d trendFlat
Δ7d
-0.6
Δ21d
-0.4
Sentiment
60
34% active weight
Current posture
7d trendSoftening
Δ7d
-13.2
Δ21d
-7.9
Why this grade
Composite grade D. Momentum 24.6 / Value 55.7 / Sentiment 59.8
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$175.37B
Beta
0.75
Shares Out
1.74B
P/E (TTM)
15.8
P/S (TTM)
5.02
P/FCF (TTM)
76.53
Rev YoY
+7.8%
EPS YoY
-17.1%
Gross Margin
+52.8%
Op Margin
+17.5%
Net Debt
$5.2B
Current Ratio
1.39
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology